Sagimet Biosciences reports Q2 GAAP EPS of -$0.26, in line with estimates

Earnings

โดย Seeking Alpha·

Summary · why it matters

Sagimet Biosciences reported second-quarter 2026 GAAP earnings per share of -$0.26, matching analyst expectations. The company held cash, cash equivalents, and marketable securities of $257.6 million as of June 30, 2026, which it expects will fund current operations through 2028, including through the data readout of its denifanstat Phase 3 trial in moderate to severe acne.

Sagimet Biosciences Inc. Series A Common Stock ±

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks

Sagimet Biosciences Inc. Series A Common Stock

SGMT

± MixedCapitalrelevance

Reports Q2 EPS in line with estimates and cash runway through 2028, but no significant positive or negative surprise.

Sagimet Biosciences reports Q2 GAAP EPS of -$0.26, in line with estimates

Impact on stocks 1

Theme Impact

Off-coverage companies

Related news